15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
22:49 , Jul 23, 2018 |  BC Extra  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
15:40 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

Reviving NK cells

Researchers from the University of Science and Technology of China have identified a key role for TIGIT in NK cell exhaustion that suggests immunotherapies targeting TIGIT may be useful against cancers that have failed to...
19:41 , Apr 12, 2018 |  BC Innovations  |  Translation in Brief

Shape recognition

A Cardiff University team has engineered a D-peptide that mimicked the T cell agonist activity of an influenza peptide and protected mice from infection by the virus. The findings suggest oral vaccines based on synthetic...
18:16 , Apr 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Mouse studies suggest a vaccine based on an M1-mimicking synthetic peptide could help treat influenza. Screening of a combinatorial library of D-peptides against CD8+ T cell clones specific for the immunodominant M1 peptide...
23:51 , Mar 19, 2018 |  BC Innovations  |  Translation in Brief

Crafting CAR Tregs

TxCell S.A. (Euronext:TXCL) thinks it has cracked the code on building CAR Tregs without running into the manufacturing challenges that can compromise the cells’ immunosuppressive function. The company presented data on their manufacturing process at...
19:31 , Jan 24, 2018 |  BC Innovations  |  Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the HLA-DQ8...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
19:35 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; melanoma Cell culture and mouse studies suggest inhibiting MHCI, MHCI components or the macrophage MHC1 binding partner LILRB1 could help treat pancreatic cancer and melanoma. In co-culture of human pancreatic neuroendocrine...
01:29 , Nov 29, 2017 |  BC Extra  |  Preclinical News

Researchers identify second macrophage inhibitory pathway as target for cancer immunotherapy

In a study published in Nature Immunology, researchers at Stanford University and colleagues found blocking major histocompatibility complex class I (MHCI) or leukocyte immunoglobulin-like receptor B1 (LILRB1) promoted phagocytosis of tumor cells, suggesting the pathway...